This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks Under $10 Set to Soar

Acadia Pharmaceuticals

Another under-$10 name in the biotechnology and drugs complex that's trading within range of triggering a major breakout trade is Acadia Pharmaceuticals (ACAD), which is focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. This stock is off to a monster start in 2012, with shares up over 60% so far.

This company has a catalyst on the horizon for its drug Pimavanserin, which is a treatment for patients suffering psychosis due to Parkinson's disease. Top-line results for this phase III study are expected to be released in the third quarter of 2012. As of early August, the trail is 95% enrolled, and management recently said it expects to offer data in late November to early December of this year.

>>22 Biopharma Stocks With Breakout Potential in 2012

If you take a look at the chart for Acadia Pharmaceuticals, you'll see that this stock has been uptrending strong for the last three months, with shares rising from a low of $1.29 to its recent high of $1.96 a share. During that uptrend, shares of Acadia Pharmaceuticals have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed ACAD within range of triggering a major breakout trade.

Traders should now look for long-biased trades in ACAD once it manages to break out above some near-term overhead resistance levels at $1.85 to $1.96 with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 374,948 shares. If that breakout triggers soon, then look for ACAD to re-test and possibly take out its next significant overhead resistance levels at $2.30 to $3.30 a share. Any high-volume move above $3.30 will setup ACAD to trend north of $5 a share, which happens to be where it traded back in 2009.

Traders can look to buy ACAD off any weakness, and simply use a stop at around its 50-day moving average of $1.63 or even down towards its 200-day moving average of $1.52 a share, depending on where you enter. One can also get long once $1.85 to $1.96 a share are taken out with high volume, and then use a stop at around $1.70 to $1.63 a share. I would add to either position once $2.30 gets taken out with volume, and then once $3.30 a share gets smashed with volume.

4 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs